Cabazitaxel

(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-ylbenzoat

White solid

Fixed

• Insoluble in water
• Soluble in ethanol

Template: Infobox chemical / molecular formula search available

Cabazitaxel (trade name Jevtana ®, manufactured by Sanofi- Aventis) is semi-synthetically derived cytostatic drug from the group of taxanes for the treatment of advanced prostate cancer after treatment with a different chemotherapy; it makes sense in castration-resistant cancer as an additional line of therapy. Cabazitaxel is one of the microtubule inhibitors. It inhibits cell division phase in the formation of the spindle apparatus ( mitotic inhibitors, cytotoxic effect ).

Synthesis

Cabazitaxel is semi- synthetically from the natural product 10 - deacetyl baccatin III, who by extraction from yew needles (Taxus sp. ) Is obtained.

Areas of application

Cabazitaxel is used as second-line treatment after docetaxel in castration-resistant prostate cancer. Every three weeks, cabazitaxel is administered daily at a dose of 25 mg/m2 as a one-hour infusion in combination with 10 mg of prednisone. The patient must be at least 1500 neutrophils per cubic millimeter ( ul) having blood as it can lead to serious infections otherwise.

Side effects

Allergic reactions to cabazitaxel are possible. Other side effects include ( febrile ) neutropenia, thrombocytopenia and diarrhea, among other things, further abdominal pain, back pain, fatigue and fever.

Early benefit assessment ( § 35a SGB V)

A resolution regarding the " added value " of cabazitaxel - because § 35a SGB V ( AMNOG ) (early benefit assessment ) - by the Federal Joint Committee (G -BA) took place in late March 2012. According to G -BA is an indication of little added value was found for the drug cabazitaxel for a group of patients.